{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:11:45Z","timestamp":1790777505992,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T00:00:00Z","timestamp":1670716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>CD34 and HLA\u2010DR negativity is often used as a characteristic immunophenotypic feature of acute promyelocytic leukaemia (APL) that differentiates APL from other subtypes of acute myeloid leukaemia (AML). However, other subtypes of AML, without expression of CD34 and HLA\u2010DR antigens, have also been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed the HLA\u2010DR negative de novo non\u2010APL AML cases by dividing HLA\u2010DR negative non\u2010APL group into 2 sub\u2010groups based on CD34 expression and compared the characteristics of CD34 negative HLA\u2010DR negative with CD34 positive HLA\u2010DR negative non\u2010APL AML cases with respect to morphologic, immunophenotypic, molecular and clinical parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 70 cases (8.54%) which were CD34 negative HLA\u2010DR negative and 52 cases (6.34%) were CD34 positive HLA\u2010DR negative. The median age at diagnosis was higher in CD34 negative HLA\u2010DR negative AML than in CD34 positive HLA\u2010DR negative AML group (38\u2009years vs. 12\u2009years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). DIC rate was higher in CD34 negative HLA\u2010DR negative group than the other group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median total leucocyte count was higher with higher blast count in peripheral blood and bone marrow in CD34 negative HLA\u2010DR negative AML cases than the other group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). CD34 negative HLA\u2010DR negative AML was more associated with normal karyotype (96.2% vs. 38.5%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), <jats:italic>NPM1<\/jats:italic> mutation (67.8% vs. 8.3%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and <jats:italic>FLT\u2010ITD<\/jats:italic> mutation (37.3% vs. 13.9%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In CD34 negative HLA\u2010DR negative group, 16 cases had co\u2010occurrence of <jats:italic>NPM1<\/jats:italic> and <jats:italic>FLT3\u2010ITD<\/jats:italic> mutations, whereas no case of CD34 positive HLA\u2010DR negative group had such dual mutation positivity. There was poor median overall survival [3.8\u00a0months (95%CI: 2.3\u20137.8\u00a0months) vs. 20.4\u00a0months (95% CI: 12.8\u201325.7\u00a0months); <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0148] in CD34 positive HLA\u2010DR negative AML than CD34 negative HLA\u2010DR negative AML cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found that the CD34 negative HLADR negative non APL AML is highly associated with <jats:italic>NPM1<\/jats:italic> and <jats:italic>FLT3\u2010ITD<\/jats:italic> mutation, older age at diagnosis, DIC, higher total leucocyte count, higher blast counts and normal karyotype in comparison to CD34 positive HLA\u2010DR negative AML group. Co\u2010occurrence of <jats:italic>NPM1<\/jats:italic> and <jats:italic>FLT3\u2010ITD<\/jats:italic> mutation was also exclusively seen in CD34 negative HLA\u2010DR negative group. There was poor overall survival in CD34 positive HLA\u2010DR negative AML than CD34 negative HLA\u2010DR negative AML cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.14007","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T07:40:49Z","timestamp":1670830849000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["<scp>CD34<\/scp> negative <scp>HLA\u2010DR<\/scp> negative acute myeloid leukaemia: A higher association with <scp><i>NPM1<\/i><\/scp> and <scp><i>FLT3\u2010ITD<\/i><\/scp> mutations"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1759-7857","authenticated-orcid":false,"given":"Smeeta","family":"Gajendra","sequence":"first","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshi","family":"Thakral","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-3425","authenticated-orcid":false,"given":"Sanjeev Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-0868","authenticated-orcid":false,"given":"Garima","family":"Jain","sequence":"additional","affiliation":[{"name":"ICMR National Institute of Pathology (NIOP)  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeet Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-6081","authenticated-orcid":false,"given":"Sandeep","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Oncology, Dr. BRAIRCH AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Datt","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Biostatistics AIIMS  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,11]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Flow cytometry in neoplastic hematology: morphologic\u2013immunophenotypic correlation","author":"Gorczyca W","year":"2017"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20475"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12754"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.09.017"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31821503c8"},{"issue":"7","key":"e_1_2_9_7_1","first-page":"547","article-title":"Clinical analysis of HLA\u2010DR\u2010negative non\u2010M3 AML","volume":"48","author":"Mori H","year":"2007","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2007.27.5.313"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402865"},{"issue":"3","key":"e_1_2_9_10_1","first-page":"150","article-title":"HLA\u2010Dr negative acute non\u2010lymphocytic leukemia","volume":"28","author":"Lazarchick J","year":"1998","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001228"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007198"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1616068"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.1011"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.5858\/2003-127-42-FCAOA"},{"key":"e_1_2_9_20_1","first-page":"200","article-title":"CD34\u2010negative is highly associated with T (15;17), T (V; 11q23) and the NPM1\u2010mutation subtypes in 343 newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Zhu HH","year":"2016","journal-title":"Chemo Open Access"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20368"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403458"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13357"},{"key":"e_1_2_9_24_1","first-page":"823","article-title":"CD34 expression in adult acute myeloid leukemia is an independent poor prognostic factor","author":"Amer A","year":"2020","journal-title":"Zagazig Univ Med J"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.14007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T22:52:32Z","timestamp":1692571952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.14007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,11]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/ijlh.14007"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.14007","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,11]]},"assertion":[{"value":"2022-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}